Latest action: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill to expand patient access to new medical treatments not yet fully approved by FDA.
The problem
Patients with serious diseases sometimes cannot access promising new treatments because the FDA approval process takes years. Patients want faster access to potentially life-saving medicines.
The proposal
Allows patients with serious conditions to request access to experimental drugs earlier in the testing process. Requires companies to consider these requests and report on their decisions.
The impact
Patients with serious illnesses would get earlier access to new drugs. Drug companies face new reporting requirements. FDA maintains oversight of safety.
Patients with serious diseases could try promising new treatments years before normal FDA approval. This gives hope to people with conditions that have few current treatment options. For some patients, waiting through normal approval could mean the difference between life and death.
Companies may invest more in developing treatments for rare or serious diseases if patients can access them sooner. Earlier feedback from patient use could help improve treatments. This could speed up overall medical progress.
Gives patients more say in their own medical care. Allows informed people to choose experimental treatments rather than only using approved options. Respects individual decision-making about health risks.
Real-world patient use of experimental drugs provides valuable information about how treatments work outside controlled lab settings. This data could help FDA make better approval decisions.
Experimental drugs have not completed all safety testing. Patients could experience serious side effects or harm. Drugs that seemed promising in early tests sometimes fail later or cause unexpected problems.
Desperate patients might try unproven treatments instead of using proven medicine. Companies might market drugs before enough evidence exists that they work. Patients could waste time and money on ineffective treatments.
If patients are harmed by experimental drugs, it is unclear who is responsible. Companies might face fewer consequences for safety problems. Patients could lose legal protections if something goes wrong.
Companies might rush drugs to market to take advantage of early access before full testing. This could reduce motivation to complete thorough safety studies. The FDA's standard approval process could be undermined.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.